文献速递肝肾功能剂量调整特殊人群用药

肝硬化对巴塞尔表型鸡尾酒六种底物药代动力学的影响各异

Liver Cirrhosis Affects the Pharmacokinetics of the Six Substrates of the Basel Phenotyping Cocktail Differently.
PubMed 文献 · Clin Pharmacokinet · 2022-05-16

该研究采用巴塞尔表型鸡尾酒法,在16例Child A、15例Child B、5例Child C肝硬化患者及12名匹配对照中评估六种CYP探针药的药代动力学。结果显示肝硬化对CYP同工酶活性的影响因酶而异,Child C患者中CYP2C19、CYP2D6、CYP3A、CYP1A2和CYP2B6代谢比值分别降低92%、73%、43%、66%和47%,而CYP2C9不变。

要点

  • 肝硬化对CYP同工酶活性影响不均一,CYP2C19和CYP2D6抑制最显著。
  • Child C肝硬化患者CYP2C19代谢比值降低92%,CYP2D6降低73%。
  • CYP2C9活性(4-羟基氟比洛芬/氟比洛芬比值)在肝硬化中保持不变。

核心结论

  • 肝硬化对不同CYP同工酶活性的影响存在差异,需据此考虑肝硬化患者的药物剂量调整。

主要发现

  • Child C肝硬化患者咖啡因(CYP1A2)消除速率降低51%。
  • Child C肝硬化患者奥美拉唑(CYP2C19)、美托洛尔(CYP2D6)和咪达唑仑(CYP3A)消除速率分别降低75%、37%和60%。
  • Child C肝硬化患者代谢比值(AUC0-24h代谢物/原药)下降:旁黄嘌呤/咖啡因(CYP1A2)66%、8-羟基依非韦伦/依非韦伦(CYP2B6)47%、5-羟基奥美拉唑/奥美拉唑(CYP2C19)92%、α-羟基美托洛尔/美托洛尔(CYP2D6)73%、1'-羟基咪达唑仑/咪达唑仑(CYP3A)43%。
  • 4-羟基氟比洛芬/氟比洛芬(CYP2C9)代谢比值在肝硬化患者中保持不变。
  • 肝硬化对低至中等提取率药物依非韦伦和氟比洛芬的药代动力学影响轻微。

临床怎么用

  • 临床对肝硬化患者使用主要经CYP2C19、CYP2D6、CYP3A、CYP1A2或CYP2B6代谢的药物时,应警惕暴露量升高并考虑剂量调整。
  • 经CYP2C9代谢的药物在肝硬化患者中可能无需仅因肝硬化而调整剂量,但仍需结合其他因素评估。

局限性

  • Child C肝硬化患者样本量较小(n=5),结果需在更大样本中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Activities of hepatic cytochrome P450 enzymes (CYPs) are relevant for hepatic clearance of drugs and known to be decreased in patients with liver cirrhosis. Several studies have reported the effect of liver cirrhosis on CYP activity, but the results are partially conflicting and for some CYPs lacking. OBJECTIVE: In this study, we aimed to investigate the CYP activity in patients with liver cirrhosis with different Child stages (A-C) using the Basel phenotyping cocktail approach. METHODS: We assessed the pharmacokinetics of the six compounds and their CYP-specific metabolites of the Basel phenotyping cocktail (CYP1A2: caffeine, CYP2B6: efavirenz, CYP2C9: flurbiprofen, CYP2C19: omeprazole, CYP2D6: metoprolol, CYP3A: midazolam) in patients with liver cirrhosis (n = 16 Child A cirrhosis, n = 15 Child B cirrhosis, n = 5 Child C cirrhosis) and matched control subjects (n = 12). RESULTS: While liver cirrhosis only marginally affected the pharmacokinetics of the low to moderate extraction drugs efavirenz and flurbiprofen, the elimination rate of caffeine was reduced by 51% in patients with Child C cirrhosis. For the moderate to high extraction drugs omeprazole, metoprolol, and midazolam, liver cirrhosis decreased the elimination rate by 75%, 37%, and 60%, respectively, increased exposure, and decreased the apparent systemic clearance (clearance/bioavailability). In patients with Child C cirrhosis, the metabolic ratio (ratio of the area under the plasma concentration-time curve from 0 to 24 h of the metabolite to the parent compound), a marker for CYP activity, decreased by 66%, 47%, 92%, 73%, and 43% for paraxanthine/caffeine (CYP1A2), 8-hydroxyefavirenz/efavirenz (CYP2B6), 5-hydroxyomeprazole/omeprazole (CYP2C19), α-hydroxymetoprolol/metoprolol (CYP2D6), and 1'-hydroxymidazolam/midazolam (CYP3A), respectively. In comparison, the metabolic ratio 4-hydroxyflurbiprofen/flurbiprofen (CYP2C9) remained unchanged. CONCLUSIONS: Liver cirrhosis affects the activity of CYP isoforms differently. This variability must be considered for dose adjustment of drugs in patients with liver cirrhosis. CLINICAL TRIAL REGISTRATION: NCT03337945.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Duthaler U, Bachmann F, Suenderhauf C, et al. Liver Cirrhosis Affects the Pharmacokinetics of the Six Substrates of the Basel Phenotyping Cocktail Differently. Clin Pharmacokinet. 2022. PMID: 35570253. doi:10.1007/s40262-022-01119-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。